Registry for patients with CABP2-related hearing impairment
Patient Registry for Individuals With CABP2-Associated Hearing Loss
This study is collecting information from people with hearing loss caused by CABP2 gene changes to learn more about this condition and how it affects them.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 100 (estimated) |
| Sex | All |
| Sponsor | University Medical Center Goettingen Academic / other |
| Locations | 1 site (Göttingen) |
| Trial ID | NCT06680934 on ClinicalTrials.gov |
What this trial studies
This registry collects detailed information about individuals diagnosed with hearing impairment due to CABP2 gene variants. It aims to gather molecular genetic data and clinical information to support a natural history study of this condition. The study is conducted in both German and English and adheres to ethical guidelines approved by the University Medical Center Goettingen's Ethics Committee.
Who should consider this trial
Good fit: Ideal candidates are individuals with a confirmed molecular genetic diagnosis of biallelic variants in the CABP2 gene and associated audiometry results.
Not a fit: Patients with hearing impairment due to non-CABP2 genetic causes will not benefit from this registry.
Why it matters
Potential benefit: If successful, this registry could enhance understanding of CABP2-related hearing impairment and improve patient management.
How similar studies have performed: While this registry approach is common in genetic research, the specific focus on CABP2-related auditory synaptopathy is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * A molecular genetic diagnosis involving biallelic variants in CAPB2 and audiometry Exclusion Criteria: * Patients with evidence of non-CABP2 molecular genetic diagnoses
Where this trial is running
Göttingen
- University Medical Center Goettingen — Göttingen, Germany (Recruiting)
Study contacts
- Principal investigator: Bernd Wollnik, MD — University Medical Center Goettingen
- Study coordinator: Barbara Vona, PhD
- Email: barbara.vona@med.uni-goettingen.de
- Phone: +49-551-38-51337
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.